

Fabien Zoulim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3470392/publications.pdf>

Version: 2024-02-01

289
papers

26,446
citations

6613

79
h-index

7160

153
g-index

309
all docs

309
docs citations

309
times ranked

16576
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 2017, 67, 370-398.	3.7	3,803
2	Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature Reviews Drug Discovery, 2013, 12, 447-464.	46.4	925
3	Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology, 2004, 126, 1750-1758.	1.3	804
4	Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. Gastroenterology, 2009, 137, 1593-1608.e2.	1.3	614
5	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	13.7	449
6	Woodchuck hepatitis virus X protein is required for viral infection in vivo. Journal of Virology, 1994, 68, 2026-2030.	3.4	430
7	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology, 2017, 152, 142-156.e2.	1.3	420
8	Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology, 2007, 46, 254-265.	7.3	418
9	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) â€” NCT01514890. Journal of Hepatology, 2013, 59, 434-441.	3.7	407
10	Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. Journal of Hepatology, 2011, 55, 996-1003.	3.7	361
11	Therapeutic strategies for hepatitis B virus infection: towards a cure. Nature Reviews Drug Discovery, 2019, 18, 827-844.	46.4	352
12	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	8.1	342
13	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
14	Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes. Gastroenterology, 2014, 147, 48-64.	1.3	293
15	Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. Journal of Hepatology, 2003, 39, 1085-1089.	3.7	288
16	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	7.3	269
17	Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2007, 5, 890-897.	4.4	268
18	The way forward in HCV treatment â€” finding the right path. Nature Reviews Drug Discovery, 2007, 6, 991-1000.	46.4	267

#	ARTICLE	IF	CITATIONS
19	Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. <i>Hepatology</i> , 2005, 41, 1391-1398.	7.3	260
20	Hepatitis B virus genetic variability and evolution. <i>Virus Research</i> , 2007, 127, 164-176.	2.2	246
21	Hepatitis B cure: From discovery to regulatory approval. <i>Hepatology</i> , 2017, 66, 1296-1313.	7.3	235
22	Towards an HBV cure: state-of-the-art and unresolved questionsâ€”report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	12.1	234
23	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.3	232
24	New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. <i>Journal of Hepatology</i> , 2005, 42, 302-308.	3.7	216
25	Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. <i>Gastroenterology</i> , 2008, 134, 405-415.	1.3	215
26	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conferenceâ€. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	3.7	208
27	Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 615-625.	3.7	204
28	Management of Antiviral Resistance in Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2004, 9, 679-693.	1.0	200
29	Early Detection of Viral Resistance by Determination of Hepatitis B Virus Polymerase Mutations in Patients Treated by Lamivudine for Chronic Hepatitis B. <i>Hepatology</i> , 2000, 32, 1078-1088.	7.3	197
30	Hepatitis B cure: From discovery to regulatory approval. <i>Journal of Hepatology</i> , 2017, 67, 847-861.	3.7	189
31	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. <i>Gastroenterology</i> , 2018, 155, 1436-1450.e6.	1.3	183
32	Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. <i>Journal of Hepatology</i> , 2008, 48, 747-755.	3.7	180
33	HBVdb: a knowledge database for Hepatitis B Virus. <i>Nucleic Acids Research</i> , 2013, 41, D566-D570.	14.5	178
34	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015, 64, 1289-1295.	12.1	178
35	New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. <i>Journal of Hepatology</i> , 2016, 64, S117-S131.	3.7	172
36	Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy. <i>Journal of Clinical Microbiology</i> , 2000, 38, 702-707.	3.9	162

#	ARTICLE	IF	CITATIONS
37	Selection of a Multiple Drug-Resistant Hepatitis B Virus Strain in a Liver-Transplanted Patient. <i>Gastroenterology</i> , 2006, 131, 1253-1261.	1.3	160
38	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013, 62, 760-765.	12.1	159
39	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011, 54, 443-451.	7.3	150
40	Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3729-3734.	3.9	146
41	Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. <i>Journal of Hepatology</i> , 2007, 46, 531-538.	3.7	146
42	Hepatitis B: Reflections on the current approach to antiviral therapy. <i>Journal of Hepatology</i> , 2008, 48, S2-S19.	3.7	142
43	Molecular Genetics of HBV Infection. <i>Antiviral Therapy</i> , 2010, 15, 3-14.	1.0	139
44	Global strategies are required to cure and eliminate HBV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 239-248.	17.8	134
45	Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1207-1217.e3.	1.3	133
46	Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e26315.	2.5	132
47	How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. <i>Journal of Hepatology</i> , 2017, 67, 1281-1297.	3.7	132
48	Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. <i>Journal of General Virology</i> , 2009, 90, 127-135.	2.9	128
49	Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis B. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021501-a021501.	6.2	128
50	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1. <i>Gut</i> , 2015, 64, 1824-1833.	12.1	128
51	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , 2012, 12, 341-353.	9.1	127
52	Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. <i>Antiviral Research</i> , 2004, 64, 1-15.	4.1	126
53	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 897-909.	3.7	125
54	Control of hepatitis B virus replication by innate response of HepaRG cells. <i>Hepatology</i> , 2010, 51, 63-72.	7.3	124

#	ARTICLE	IF	CITATIONS
55	Hepatitis B virus resistance to antiviral drugs: where are we going?. <i>Liver International</i> , 2011, 31, 111-116.	3.9	118
56	Progress towards elimination goals for viral hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 533-542.	17.8	118
57	Management of treatment failure in chronic hepatitis B. <i>Journal of Hepatology</i> , 2012, 56, S112-S122.	3.7	116
58	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. <i>Journal of Hepatology</i> , 2012, 56, 520-526.	3.7	114
59	Early inhibition of hepatocyte innate responses by hepatitis B virus. <i>Journal of Hepatology</i> , 2015, 63, 1314-1322.	3.7	114
60	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	12.1	112
61	Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. <i>Aids</i> , 2006, 20, 419-427.	2.2	107
62	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 1093-1102.	3.7	107
63	Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. <i>Antiviral Research</i> , 2004, 64, 1-15.	4.1	105
64	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010, 52, 493-500.	3.7	103
65	Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. <i>Hepatology</i> , 1999, 29, 230-237.	7.3	102
66	Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. <i>Hepatology</i> , 2002, 36, 710-722.	7.3	102
67	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	3.7	100
68	Reasons to consider earlier treatment of chronic HBV infections. <i>Gut</i> , 2012, 61, 333-336.	12.1	98
69	A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. <i>Hepatology</i> , 2004, 40, 855-864.	7.3	97
70	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 14	7.3	96
71	Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 425-433.	3.2	91
72	Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. <i>Journal of Hepatology</i> , 2018, 68, 922-931.	3.7	88

#	ARTICLE	IF	CITATIONS
73	The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. <i>Antiviral Research</i> , 2018, 149, 211-220.	4.1	86
74	Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. <i>Journal of Hepatology</i> , 2016, 65, 683-691.	3.7	84
75	Evolution of Hepatitis B Virus Polymerase Gene Sequence during Famciclovir Therapy for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2000, 181, 1221-1233.	4.0	83
76	Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	83
77	Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. <i>Journal of Viral Hepatitis</i> , 2010, 17, 887-895.	2.0	82
78	Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. <i>Aids</i> , 2005, 19, 907-915.	2.2	81
79	Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2014, 60, 715-722.	3.7	81
80	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	1.3	81
81	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. <i>Gastroenterology</i> , 2020, 159, 521-533.e9.	1.3	80
82	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	3.7	79
83	Characterization of the Antiviral Effect of 2'-,3'-Dideoxy-2',3'-Dideohydro-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 111-122.	3.2	78
84	N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. <i>Journal of Hepatology</i> , 2014, 60, 515-522.	3.7	77
85	Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion. <i>Clinical Infectious Diseases</i> , 2007, 45, 624-632.	5.8	76
86	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015, 62, 1047-1055.	3.7	76
87	The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. <i>Antiviral Research</i> , 2011, 92, 271-276.	4.1	75
88	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	7.3	75
89	HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. <i>Antiviral Research</i> , 2016, 136, 19-31.	4.1	73
90	Current treatments for chronic hepatitis B virus infections. <i>Current Opinion in Virology</i> , 2016, 18, 109-116.	5.4	70

#	ARTICLE	IF	CITATIONS
91	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
92	Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates. <i>Hepatology</i> , 2012, 56, 2116-2124.	7.3	68
93	A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. <i>Journal of Viral Hepatitis</i> , 2006, 13, 278-288.	2.0	66
94	Treatment of hepatitis B virus-infected cells with α -glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. <i>Antiviral Research</i> , 2007, 76, 30-37.	4.1	66
95	Persistent viremia in human immunodeficiency virus/hepatitis B coinfecting patients undergoing long-term tenofovir: Virological and clinical implications. <i>Hepatology</i> , 2014, 60, 497-507.	7.3	66
96	Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3072-3083.	2.3	64
97	Antiviral therapy of chronic hepatitis B. <i>Antiviral Research</i> , 2006, 71, 206-215.	4.1	63
98	Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?. <i>Journal of Viral Hepatitis</i> , 2007, 14, 29-36.	2.0	63
99	Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. <i>Journal of Hepatology</i> , 2019, 71, 1086-1098.	3.7	62
100	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 473-485.	3.7	62
101	In Vitro Characterization of Viral Fitness of Therapy-Resistant Hepatitis B Variants. <i>Gastroenterology</i> , 2009, 136, 168-176.e2.	1.3	61
102	Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. <i>Antiviral Research</i> , 2016, 130, 36-45.	4.1	61
103	Can we cure hepatitis B virus with novel direct-acting antivirals?. <i>Liver International</i> , 2020, 40, 27-34.	3.9	61
104	Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. <i>Journal of Hepatology</i> , 2015, 62, 56-63.	3.7	60
105	Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. <i>Liver International</i> , 2017, 37, 1122-1127.	3.9	60
106	Polo-like kinase 1 is a proviral host factor for hepatitis B virus replication. <i>Hepatology</i> , 2017, 66, 1750-1765.	7.3	60
107	Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. <i>Journal of Viral Hepatitis</i> , 1998, 5, 193-198.	2.0	59
108	Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. <i>Journal of Hepatology</i> , 2015, 63, 1077-1085.	3.7	59

#	ARTICLE	IF	CITATIONS
109	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TTS	22.1	59
110	Novel targets for hepatitis B virus therapy. <i>Liver International</i> , 2017, 37, 33-39.	3.9	58
111	Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. <i>Scientific Reports</i> , 2018, 8, 5390.	3.3	57
112	Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. <i>Journal of Hepatology</i> , 2021, 75, 706-717.	3.7	57
113	Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. <i>Liver International</i> , 2013, 33, 116-124.	3.9	56
114	Immune-modulators to combat hepatitis B virus infection: From IFN- α to novel investigational immunotherapeutic strategies. <i>Antiviral Research</i> , 2015, 122, 69-81.	4.1	56
115	Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 388-399.	3.3	56
116	Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. <i>Journal of Hepatology</i> , 2000, 32, 307-316.	3.7	55
117	Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 279-282.	2.1	54
118	Rolling Circle Amplification, a Powerful Tool for Genetic and Functional Studies of Complete Hepatitis B Virus Genomes from Low-Level Infections and for Directly Probing Covalently Closed Circular DNA. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3068-3073.	3.2	54
119	Inhibitory Effect of 2-Fluoro-5-Methyl- β -Arabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 369-376.	3.2	54
120	Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	3.7	54
121	Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. <i>Journal of Hepatology</i> , 2020, 73, 40-51.	3.7	53
122	Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2011, 18, e29-39.	2.0	52
123	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL/AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	7.3	52
124	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2021, 74, 1064-1074.	3.7	52
125	Innate Antiviral Immune Responses to Hepatitis B Virus. <i>Viruses</i> , 2010, 2, 1394-1410.	3.3	51
126	HBV cure: why, how, when?. <i>Current Opinion in Virology</i> , 2016, 18, 135-143.	5.4	50

#	ARTICLE	IF	CITATIONS
127	Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. <i>Antiviral Research</i> , 2017, 145, 14-19.	4.1	49
128	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	4.4	49
129	In Vitro Models for Studying Hepatitis B Virus Drug Resistance. <i>Seminars in Liver Disease</i> , 2006, 26, 171-180.	3.6	48
130	Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 464-469.	3.7	48
131	Antiviral Activity of Î²-Dideoxy-3'-Dideoxy-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1065-1077.	3.2	45
132	Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV/hepatitis B virus-infected patients. <i>Aids</i> , 2012, 26, 939-949.	2.2	45
133	Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. <i>Liver International</i> , 2012, 32, 1477-1492.	3.9	45
134	Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity. <i>Gut</i> , 2016, 65, 144-154.	12.1	45
135	Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. <i>Current Opinion in Virology</i> , 2018, 30, 80-89.	5.4	44
136	In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2240-2243.	3.2	43
137	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1013-1018.	5.8	43
138	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020, 4, 8-20.	4.3	43
139	Rates and determinants of hepatitis B e antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfecting with HIV and hepatitis B virus. <i>Aids</i> , 2015, 29, 1963-1973.	2.2	42
140	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	2.2	42
141	Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV) Coinfected Patients With High HBV Replication. <i>Clinical Infectious Diseases</i> , 2018, 66, 112-120.	5.8	42
142	Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. <i>Journal of General Virology</i> , 2008, 89, 1819-1828.	2.9	41
143	Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. <i>Journal of Hepatology</i> , 2005, 42, 279-281.	3.7	40
144	Hepatitis B virus: From diagnosis to treatment. <i>Pathologie Et Biologie</i> , 2010, 58, 245-253.	2.2	40

#	ARTICLE	IF	CITATIONS
145	European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of Genotypes. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2792-2800.	3.9	39
146	Non-invasive biomarkers for chronic hepatitis B virus infection management. <i>Antiviral Research</i> , 2019, 169, 104553.	4.1	38
147	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 118-126.	2.0	38
148	Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants. <i>Antiviral Therapy</i> , 2008, 13, 381-388.	1.0	38
149	High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. <i>Hepatology</i> , 2013, 58, 912-922.	7.3	37
150	Antiviral Therapy of Chronic Hepatitis B: Prevention of Drug Resistance. <i>Clinics in Liver Disease</i> , 2007, 11, 869-892.	2.1	36
151	Are novel combination therapies needed for chronic hepatitis B?. <i>Antiviral Research</i> , 2012, 96, 256-259.	4.1	36
152	Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines. <i>Journal of Innate Immunity</i> , 2018, 10, 339-348.	3.8	36
153	Entecavir: A new treatment option for chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2006, 36, 8-12.	3.1	34
154	Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. <i>Journal of Medical Virology</i> , 2009, 81, 1336-1342.	5.0	34
155	Management and prevention of drug resistance in chronic hepatitis B. <i>Liver International</i> , 2009, 29, 108-115.	3.9	34
156	Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. <i>Hepatology</i> , 2012, 56, 1706-1718.	7.3	34
157	Very-Low-Density Lipoprotein (VLDL)-Producing and Hepatitis C Virus-Replicating HepG2 Cells Secrete No More Lipoviroparticles than VLDL-Deficient Huh7.5 Cells. <i>Journal of Virology</i> , 2013, 87, 5065-5080.	3.4	34
158	Clinical relevance of the study of hepatitis B virus covalently closed circular <scp>DNA</scp>. <i>Liver International</i> , 2016, 36, 72-77.	3.9	34
159	HBV 2021: New therapeutic strategies against an old foe. <i>Liver International</i> , 2021, 41, 15-23.	3.9	34
160	Innate response to hepatitis B virus infection: Observations challenging the concept of a stealth virus. <i>Hepatology</i> , 2009, 50, 1692-1695.	7.3	33
161	Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1185-1190.	1.0	33
162	Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. <i>Journal of Hepatology</i> , 2001, 34, 114-122.	3.7	31

#	ARTICLE	IF	CITATIONS
163	Effect of a Combination of Clevudine and Emtricitabine with Adenovirus-Mediated Delivery of Gamma Interferon in the Woodchuck Model of Hepatitis B Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2683-2692.	3.2	31
164	Hepatitis C virus infection propagates through interactions between Syndecan-1 and CD81 and impacts the hepatocyte glycocalyx. <i>Cellular Microbiology</i> , 2017, 19, e12711.	2.1	31
165	Challenges to a Cure for HBV Infection. <i>Seminars in Liver Disease</i> , 2017, 37, 231-242.	3.6	31
166	New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. <i>Journal of Clinical Microbiology</i> , 1992, 30, 1111-1119.	3.9	31
167	A quasi-monoclonal anti-HBs response can lead to immune escape of "wild-type" hepatitis B virus. <i>Journal of General Virology</i> , 2005, 86, 1687-1693.	2.9	30
168	Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons From Experimental and Clinical Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1011-1013.	4.4	30
169	Sulfur isotope analysis by MC-ICP-MS and application to small medical samples. <i>Journal of Analytical Atomic Spectrometry</i> , 2016, 31, 1002-1011.	3.0	30
170	Biological basis for functional cure of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 786-794.	2.0	30
171	Standardized One-Step Real-Time Reverse Transcription-PCR Assay for Universal Detection and Quantification of Hepatitis Delta Virus from Clinical Samples in the Presence of a Heterologous Internal-Control RNA. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2126-2128.	3.9	28
172	Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. <i>PLoS Pathogens</i> , 2020, 16, e1008593.	4.7	28
173	Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. <i>BMC Medicine</i> , 2017, 15, 217.	5.5	27
174	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 583-605.	3.7	27
175	Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients. <i>Scientific Reports</i> , 2020, 10, 21097.	3.3	26
176	Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus. <i>Hepatology</i> , 2021, 73, 861-864.	7.3	26
177	New Nucleic Acid Diagnostic Tests in Viral Hepatitis. <i>Seminars in Liver Disease</i> , 2006, 26, 309-317.	3.6	25
178	Management of patients with decompensated hepatitis B virus associated cirrhosis. <i>Liver Transplantation</i> , 2008, 14, S1-S7.	2.4	25
179	How to improve access to therapy in hepatitis B patients. <i>Liver International</i> , 2018, 38, 115-121.	3.9	25
180	New challenges in viral hepatitis. <i>Gut</i> , 2012, 61, i1-i5.	12.1	24

#	ARTICLE	IF	CITATIONS
181	Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. <i>Journal of Hepatology</i> , 2013, 59, 684-695.	3.7	24
182	Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. <i>Journal of Viral Hepatitis</i> , 2013, 20, 131-140.	2.0	23
183	Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. <i>Journal of Viral Hepatitis</i> , 2014, 21, e98-e107.	2.0	23
184	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. <i>Antiviral Research</i> , 2011, 92, 90-95.	4.1	22
185	Targeting Innate Immunity: A New Step in the Development of Combination Therapy for Chronic Hepatitis B. <i>Gastroenterology</i> , 2013, 144, 1342-1344.	1.3	22
186	Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 387-398.	2.0	22
187	DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. <i>Journal of General Virology</i> , 2008, 89, 1192-1201.	2.9	21
188	Interplay between hepatitis B virus and TLR2-mediated innate immune responses: Can restoration of TLR2 functions be a new therapeutic option?. <i>Journal of Hepatology</i> , 2012, 57, 486-489.	3.7	21
189	New approaches to the management of hepatitis C in haemophilia in 2012. <i>Haemophilia</i> , 2012, 18, 28-33.	2.1	21
190	Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from Côte d'Ivoire. <i>Antiviral Therapy</i> , 2015, 20, 643-654.	1.0	21
191	Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. <i>Genes</i> , 2019, 10, 260.	2.4	21
192	Hepatitis B virus preS2 ¹³⁸⁻¹⁵⁵ variants: A newly identified risk factor for hepatocellular carcinoma. <i>JHEP Reports</i> , 2020, 2, 100144.	4.9	21
193	Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?. <i>Hepatology</i> , 2006, 44, 1404-1407.	7.3	20
194	Microarray for Hepatitis B Virus Genotyping and Detection of 994 Mutations along the Genome. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4207-4215.	3.9	20
195	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
196	Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?. <i>Hepatology</i> , 2003, 38, 1353-1355.	7.3	19
197	Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. <i>PLoS Biology</i> , 2016, 14, e1002421.	5.6	18
198	Pathobiology of HBV mutants and clinical impact for treatment monitoring. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 309-320.	4.4	17

#	ARTICLE	IF	CITATIONS
199	Comparison between Elecsys HBsAg II and Architect HBsAg QT Assays for Quantification of Hepatitis B Surface Antigen among Patients Coinfected with HIV and Hepatitis B Virus. <i>Vaccine Journal</i> , 2012, 19, 242-248.	3.1	17
200	Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. <i>Hepatology International</i> , 2016, 10, 779-788.	4.2	17
201	Safety, pharmacokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatment-naïve chronic hepatitis B (CHB) patients without cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, S102.	3.7	17
202	CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. <i>MBio</i> , 2022, 13, e0288821.	4.1	17
203	Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication <i>in vitro</i> . <i>Antiviral Therapy</i> , 2009, 14, 131-135.	1.0	17
204	Ribavirin restores IFN α responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. <i>Gut</i> , 2016, 65, 672-682.	12.1	16
205	BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy. <i>Antiviral Research</i> , 2019, 169, 104557.	4.1	16
206	Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection. <i>Journal of Medical Virology</i> , 2019, 91, 630-641.	5.0	16
207	Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. <i>Journal of Clinical Virology</i> , 2013, 56, 306-311.	3.1	15
208	Netrin-1 Protects Hepatocytes Against Cell Death Through Sustained Translation During the Unfolded Protein Response. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 281-301.e9.	4.5	15
209	Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
210	Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. <i>Emerging Microbes and Infections</i> , 2019, 8, 354-365.	6.5	15
211	Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. <i>Journal of Hepatology</i> , 2012, 56, 1269-1275.	3.7	14
212	Performance of the cobas $\text{\textcircled{A}}$ HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105150.	3.1	14
213	Ethics and hepatitis B cure research. <i>Gut</i> , 2017, 66, 389-392.	12.1	13
214	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 66-73.	8.9	13
215	Inhibition of hepatitis B virus gene expression: A step towards functional cure. <i>Journal of Hepatology</i> , 2018, 68, 386-388.	3.7	13
216	Response-guided and unguided treatment of chronic hepatitis C. <i>Liver International</i> , 2012, 32, 64-73.	3.9	12

#	ARTICLE	IF	CITATIONS
217	Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. <i>Liver International</i> , 2009, 29, 420-426.	3.9	11
218	The life cycle of hepatitis B virus and antiviral targets. <i>Future Virology</i> , 2011, 6, 599-614.	1.8	11
219	In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. <i>Virology</i> , 2012, 433, 192-202.	2.4	11
220	Treatment failure in chronic hepatitis B. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 366-367.	17.8	10
221	Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring. <i>Advances in Hepatology</i> , 2014, 2014, 1-13.	1.3	10
222	Ultradeep Pyrosequencing and Molecular Modeling Identify Key Structural Features of Hepatitis B Virus RNase H, a Putative Target for Antiviral Intervention. <i>Journal of Virology</i> , 2014, 88, 574-582.	3.4	10
223	Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1882-1887.	2.8	10
224	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101713.	1.5	10
225	Hepatic inflammation elicits production of proinflammatory netrins through exclusive activation of translation. <i>Hepatology</i> , 2022, 76, 1345-1359.	7.3	10
226	Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus. <i>Oncogene</i> , 2017, 36, 6712-6724.	5.9	9
227	<i>Precore</i> G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus coinfected patients from Western Africa. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1121-1131.	2.0	9
228	Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1215.e1-1215.e4.	6.0	9
229	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 500-512.	3.7	9
230	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341.	3.2	8
231	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). <i>Clinical Nutrition</i> , 2022, 41, 610-619.	5.0	8
232	Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBsAg Negative Disease. <i>Viruses</i> , 2022, 14, 1070.	3.3	8
233	Does occult HBV infection have an impact on the evolution of chronic hepatitis C?. <i>Journal of Hepatology</i> , 2013, 59, 646-647.	3.7	7
234	Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 146-154.	1.6	7

#	ARTICLE	IF	CITATIONS
235	Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay. <i>Digestive and Liver Disease</i> , 2016, 48, 1351-1356.	0.9	7
236	Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution. <i>Virus Research</i> , 2017, 238, 141-147.	2.2	7
237	Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101923.	1.5	7
238	HIRA Supports Hepatitis B Virus Minichromosome Establishment and Transcriptional Activity in Infected Hepatocytes. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 527-551.	4.5	7
239	Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2022, 29, 948-957.	2.0	7
240	A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon- α and ribavirin for chronic hepatitis C virus infection. <i>Virology Journal</i> , 2018, 15, 26.	3.4	6
241	Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!. <i>Journal of Hepatology</i> , 2020, 73, 449-451.	3.7	6
242	Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e24731.	1.0	6
243	Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. <i>Cancers</i> , 2021, 13, 2270.	3.7	6
244	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	4.9	6
245	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	2.9	6
246	Heparanase-1 is upregulated by hepatitis C virus and favors its replication. <i>Journal of Hepatology</i> , 2022, 77, 29-41.	3.7	6
247	Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection. <i>JHEP Reports</i> , 2022, 4, 100480.	4.9	6
248	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPLIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450.	1.5	5
249	P0535 : Direct antiviral effects of various pattern recognition receptor (PRR) agonists in HBV-replicating hepatocytes. <i>Journal of Hepatology</i> , 2015, 62, S515-S516.	3.7	5
250	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2015, 62, S541-S542.	3.7	5
251	The variability of hepatitis B envelope is associated with HBs antigen persistence in either chronic or acute HBV genotype A infection. <i>Journal of Clinical Virology</i> , 2017, 94, 115-122.	3.1	5
252	Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 2425-2431.	2.1	5

#	ARTICLE	IF	CITATIONS
253	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 300.	2.9	5
254	Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues. <i>Journal of Viral Hepatitis</i> , 2019, 26, 278-286.	2.0	5
255	Sofosbuvir+Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020, 27, 964-973.	2.0	5
256	A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of PegIFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 37-40.	2.5	4
257	Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. <i>Antiviral Research</i> , 2018, 149, 174-178.	4.1	4
258	Hepatitis B. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, , .	17.8	4
259	Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus hepatitis B virus co-infected patients from sub-Saharan Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 437-445.	1.8	4
260	The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 145-148.	4.5	4
261	Targeting hepatitis B virus with CRISPR/Cas9 approach. <i>Journal of Hepatology</i> , 2020, 73, S841-S842.	3.7	4
262	CD81 large extracellular loop-containing fusion proteins with a dominant negative effect on HCV cell spread and replication. <i>Journal of General Virology</i> , 2017, 98, 1646-1657.	2.9	4
263	Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. <i>Antiviral Therapy</i> , 2009, 14, 131-5.	1.0	4
264	End points of therapy in chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 37-49.	3.0	3
265	335 HBV INHIBITS THE AIM-2 INFLAMMASOME IN HUMAN KUPFFER CELLS. <i>Journal of Hepatology</i> , 2013, 58, S140.	3.7	3
266	Liver capsule: Validated and potential novel targets to treat hepatitis B virus. <i>Hepatology</i> , 2015, 62, 1619-1619.	7.3	3
267	LARP1 binding to hepatitis C virus particles is correlated with intracellular retention of viral infectivity. <i>Virus Research</i> , 2019, 271, 197679.	2.2	3
268	Direct-acting antivirals and viral RNA targeting for hepatitis B cure. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 165-172.	3.8	3
269	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , 2022, 42, 249-252.	3.9	3
270	Inducers of the NF- κ B pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro. <i>JHEP Reports</i> , 2022, 4, 100415.	4.9	3

#	ARTICLE	IF	CITATIONS
271	Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study. <i>Annals of Transplantation</i> , 2022, 27, e936162.	0.9	3
272	269 CHARACTERISATION OF PATHOGEN RECOGNITION RECEPTORS IN AN HEPATOCYTE CELL LINE (HEPARC) Tj ETQg0 0 0 rgBT /Overlo	3.7	2
273	Effect of hepatitis B virus (HBV) <i>surface</i>â€“gene variability on markers of replication during treated human immunodeficiency virusâ€“HBV infection in Western Africa. <i>Liver International</i> , 2019, 39, 280-289.	3.9	2
274	Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIVâ€“hepatitis B coinfection. <i>Aids</i> , 2020, 34, 1943-1949.	2.2	2
275	External validation of the French alphaâ€“fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort â€“ a retrospective study. <i>Transplant International</i> , 2021, 34, 535-545.	1.6	2
276	HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. <i>Cancer Prevention Research</i> , 2021, 14, 581-592.	1.5	2
277	Molecular Virology and Life Cycle of Hepatitis B Virus. , 2021, , 1-27.		2
278	Adefovir serum levels do not differ between responders and nonresponders. <i>Journal of Viral Hepatitis</i> , 2011, 18, e175-8.	2.0	1
279	Treatment of human immunodeficiency virus and hepatitis B virus infections. <i>Haemophilia</i> , 2012, 18, 34-37.	2.1	1
280	Can We Predict Sustained Virologic Response to Interferon Î± Therapy in Patients With Chronic Hepatitis Delta Virus Infection?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2350-2352.	4.4	1
281	Potential effect of lamivudineâ€“induced S gene mutations on liverâ€“related pathogenesis in hepatitis D virus infection. <i>Hepatology</i> , 2017, 65, 1424-1426.	7.3	1
282	Editorial overview: Antiviral strategies: Antiviral drug design: creating new ideas against old and new bugs. <i>Current Opinion in Virology</i> , 2017, 24, v-vii.	5.4	1
283	Virology and Pathogenesis of Hepatitis B. , 2018, , 464-473.e5.		1
284	Characterization of host and viral proteins involved in the chromatinization of the hepatitis B virus minichromosome. <i>Journal of Hepatology</i> , 2018, 68, S61.	3.7	1
285	Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon version. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1160-1168.	2.0	1
286	EASL Recognition Awardee 2013. <i>Journal of Hepatology</i> , 2013, 59, 413-414.	3.7	0
287	The <sc>CUPIC</sc> algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 1002-1010.	2.0	0
288	Translational Medicine in Hepatitis B Virus: What Can We Learn from Clinical Samples?. <i>Molecular and Translational Medicine</i> , 2016, , 167-185.	0.4	0

#	ARTICLE	IF	CITATIONS
289	Hepatitis B, New Antiviral Targets. , 2020, , 122-127.		0